Howard Hughes Medical Institute

ALX Oncology Appoints Allison Dillon as Chief Business Officer

Retrieved on: 
火曜日, 5月 7, 2024
University, Cancer, CD47, Campbell Alliance, Investment, GU, Commercial, Hematology, Marketing, Trial of the century, Medulloblastoma, Bevacizumab, Growth, Roche, Consultant, Senior, Science, Patient, Acquisition, Lead, CBO, Howard Hughes Medical Institute, SAN

SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the appointment of Allison Dillon, Ph.D., as Chief Business Officer (“CBO”).

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the appointment of Allison Dillon, Ph.D., as Chief Business Officer (“CBO”).
  • “We are excited to welcome Allison to our leadership team in the midst of this promising growth period for our Company,” said Jason Lettmann, Chief Executive Officer of ALX Oncology.
  • “For over 15 years, Allison has worked to develop and deliver novel oncology products to patients with cancer.
  • “With near-term clinical trial readouts and a strong balance sheet, ALX Oncology is well positioned for greater success.

Nvelop Therapeutics Announces Members of Its Scientific Advisory Board

Retrieved on: 
木曜日, 5月 2, 2024
Health, Genetics, Other Science, Research, Science, Biotechnology, Harvard University, Danaher Corporation, Novartis, TIL, PACE, Howard Hughes Medical Institute, MIT, Gene therapy, Broad Institute, Gene editing, Duke University, Beam Therapeutics, Microbiology, Faculty, Harvard Medical School, Mammoth Biosciences, Therapy, Thomas Dudley Cabot, Aarhus University, Molecular genetics, Hospital, Arena, Biomedical engineering, RNA, Editas Medicine, Natural science, Bluebird bio, Kite Pharma, Torque, BioMarin Pharmaceutical, Patient, Gene, HSC, Massachusetts General Hospital, Growth, Pharmaceutical industry

Nvelop Therapeutics , a biotechnology company engineering programmable, non-viral vehicles for the in vivo delivery of therapeutic cargo, today announced the members of its scientific advisory board, bringing together a world-class group of experts from across the fields of gene therapy, gene editing and drug delivery.

Key Points: 
  • Nvelop Therapeutics , a biotechnology company engineering programmable, non-viral vehicles for the in vivo delivery of therapeutic cargo, today announced the members of its scientific advisory board, bringing together a world-class group of experts from across the fields of gene therapy, gene editing and drug delivery.
  • Keith Joung, M.D., Ph.D. : Dr. Joung is co-founder of Nvelop Therapeutics, and a pioneer in the development of targeted gene and epigenetic editing technologies.
  • He has co-founded multiple additional biotechnology companies, including Beam Therapeutics, Chroma Medicine, Editas Medicine, Pairwise Plants, SeQure Dx and Verve Therapeutics.
  • He is also the founder or co-founder of several biotechnology and therapeutics companies, including Beam Therapeutics, Prime Medicine, Editas Medicine, Pairwise Plants, Exo Therapeutics and Chroma Medicine.

Xaira Therapeutics Launches to Deliver Transformative Medicines by Advancing and Harnessing AI for Drug Discovery and Development

Retrieved on: 
水曜日, 4月 24, 2024
Data Management, Health, Technology, Artificial Intelligence, Pharmaceutical, Biotechnology, Ron Conway, Element, Biochemistry, ARCH Venture Partners, AI, Sequoia Capital, Systems biology, Intelligence, SVP, Medicine, Howard Hughes Medical Institute, Drug discovery, Onyx Pharmaceuticals, Food, EVP, R&D, Machine learning, Nobel Prize, NEA, Entrepreneurship, CIO, Boston Consulting Group, Therapy, Lux Capital, Foresite Capital, Executive, Lightspeed Venture Partners, Johnson & Johnson, Proteomics, Meta, Rockefeller University, Chemistry, Biology, Former, Drug development, Menlo Ventures, Interline, Stanford University, University, Food and Drug Administration, Disease, Patient, Senior advisor, Pharmaceutical industry

Xaira Therapeutics launched today on a mission to help re-engineer the way we discover and develop medicines through the end-to-end application of emerging AI technologies.

Key Points: 
  • Xaira Therapeutics launched today on a mission to help re-engineer the way we discover and develop medicines through the end-to-end application of emerging AI technologies.
  • Xaira brings together three core elements: advanced machine learning research, expansive data generation to power new models, and robust therapeutic product development.
  • With leading talent and capabilities in each area, Xaira is building a platform for drug discovery and development that will advance multiple drug programs and unlock biological understanding to inform future discovery.
  • Xaira is building significant AI research capabilities spanning fundamental computational methods development and their application to biological discovery, the design of drug-like matter, and clinical development.

Colossal Announces Expansion of Ancient DNA Academic Research Projects with $7.5M in New Investments, and Issues Call to Researchers

Retrieved on: 
月曜日, 4月 15, 2024
University, Climate Change, Education, Technology, Health, Other Science, Other Technology, Research, Genetics, Environment, Science, Stockholm University, Investment, CRISPR, Biochemistry, AI, Mammal, Partnership, Life, Love, Mastodon, Genome, Knowledge, Gene, Edelman Fossil Park, Animal, Plant, Biology, Rowan University, Bird, Climate change, DNA, University of Alaska system, Multimedia, Student, Howard Hughes Medical Institute, Genomics, Assistant professor, HUB, McMaster University, Mammoth, University of Copenhagen, Fossil, UC, Hunting

This involves implementing over $7.5M in newly committed funding to Colossal academic partners in 2024, onboarding more ancient DNA researchers, growing a larger network of ancient DNA university partners, and deploying a technology HUB for ancient DNA research.

Key Points: 
  • This involves implementing over $7.5M in newly committed funding to Colossal academic partners in 2024, onboarding more ancient DNA researchers, growing a larger network of ancient DNA university partners, and deploying a technology HUB for ancient DNA research.
  • We believe that to support a biodiverse future, we must facilitate ancient DNA research across the world.
  • Colossal will also continue to establish new partnerships with research teams around the world that are doing groundbreaking ancient DNA science.
  • If you are an ancient DNA researcher interested in joining Colossal’s upcoming ancient DNA technology HUB, please reach out [email protected] .

MyProstateScore 2.0 Clinically Validated in New JAMA Oncology Study

Retrieved on: 
木曜日, 4月 18, 2024
Lynx, Urine, Organization, U-M, University, Cancer, Urology, U24, JAMA, Prostate cancer, Prostate Cancer Foundation, ANN, Risk, JAMA Oncology, American Medical Association, Vanderbilt University, MPS2, American Cancer Society, PSA, Research, Therapy, Patient, NCI, Paper, Validation, Biopsy, EDRN, MBA, Biomarker, Howard Hughes Medical Institute, Data management, Journal, Medical imaging

ANN ARBOR, Mich., April 18, 2024 /PRNewswire/ -- Lynx Dx, a leader in innovative diagnostic solutions, hailed new peer-reviewed research published today in the Journal of the American Medical Association (JAMA) Oncology that validates the efficacy of MyProstateScore 2.0 (MPS2), the company's groundbreaking prostate cancer risk assessment test. The findings signify a major advancement in the ability to make highly accurate, comprehensive and personalized predictions by raising the performance standard for urine biomarker tests intended to detect clinically significant prostate cancer.

Key Points: 
  • Further, more than 75% of men with an elevated PSA will have a biopsy negative for clinically significant cancer.
  • In the clinical validation of MPS2 published in JAMA Oncology, scientists evaluated whether MPS2 could improve prostate cancer screening outcomes relative to existing biomarkers.
  • Key findings from the paper include:
    MPS2 was clinically validated separately in patients presenting for initial biopsy (i.e., biopsy naïve) and those presenting for a repeat biopsy (i.e., prior negative biopsy).
  • Paper cited: "Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer," JAMA Oncology.

CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB)

Retrieved on: 
火曜日, 3月 19, 2024
College, PI3, Data science, Machine, Deep learning, Therapy, Harvard University, Audit trail, Membrane protein, School, Statistics, Biotechnology, ICR, Electrical engineering, Princeton University, 3D, Dartmouth College, Breast cancer, SAB, Applied science, Drug resistance, Royal, Machine learning, Computer science, Drug discovery, Associate, Royal Society, Intelligence, Research, AKT, Cancer, University, Cancer research, DARPA, Howard Hughes Medical Institute, Drug development, Principal, AstraZeneca, Entrepreneurship, The Institute, Biomarker, Columbia University, Faculty, Saint John's College, Stanford University, Chemical engineering, Medicine, Management

LONDON – 19 March 2024 -- CHARM Therapeutics (“CHARM”, “The Company”), a 3D deep-learning research company discovering and developing transformational medicines, today announces the foundation of its Scientific Advisory Board (SAB) to provide expert insight and guidance to the Company on the optimal application of 3D deep learning, protein design and prediction in real world medicine.

Key Points: 
  • LONDON – 19 March 2024 -- CHARM Therapeutics (“CHARM”, “The Company”), a 3D deep-learning research company discovering and developing transformational medicines, today announces the foundation of its Scientific Advisory Board (SAB) to provide expert insight and guidance to the Company on the optimal application of 3D deep learning, protein design and prediction in real world medicine.
  • This pioneering technology enables CHARM to target and develop treatments for previously hard-to-drug targets in cancer and other therapeutic areas.
  • Laksh Aithani, Co-Founder, Chief Executive Officer and Board Member of CHARM Therapeutics, said: “As CHARM advances its 3D deep learning platform in discovery it’s critical to maintain aligned oversight of our priorities and keep abreast of this emerging field.
  • Founding members of CHARM’s SAB:
    David Baker, Ph.D. is a Scientific Co-Founder at CHARM and Chair of the SAB.

World-Renowned Ancient DNA Expert, HHMI Investigator, and MacArthur Award Winner Beth Shapiro, Ph.D., Joins Colossal as Chief Science Officer

Retrieved on: 
火曜日, 3月 19, 2024
Environment, Research, Genetics, Environmental Issues, Environmental Health, Biotechnology, Health, Other Science, Science, Genomics, Gene, Executive Committee, National Geographic Explorer, Woolly mammoth, Cell, University, Pennsylvania State University, Television, Life, DNA, Stanford University, CRISPR, Ice, Vertebrate Genomes Project, Hologenomics, Genome, HHMI, Colossal Biosciences, Balliol College, Oxford, Howard Hughes Medical Institute, Ecology and Evolutionary Biology, CSO, Domestication, Natural history, National academy, American Academy, Biology, Searle, George Church, Multimedia, MacArthur Fellows Program, Hunting

Colossal Biosciences, the world’s first de-extinction company, today announced that Beth Shapiro, Ph.D. , internationally renowned evolutionary molecular biologist, leader in paleogenomics, and ancient DNA expert, has joined as Chief Science Officer.

Key Points: 
  • Colossal Biosciences, the world’s first de-extinction company, today announced that Beth Shapiro, Ph.D. , internationally renowned evolutionary molecular biologist, leader in paleogenomics, and ancient DNA expert, has joined as Chief Science Officer.
  • In this role, she will oversee the continued expansion of the company’s de-extinction and conservation science teams.
  • A MacArthur “Genius Grant” Award winner and National Geographic Explorer, Beth Shapiro is a pioneer in the scientific fields of ancient DNA and paleogenomics.
  • “She’s the author of inspiring books 'How to Clone a Mammoth' and 'Life as We Made It,' plus an HHMI and MacArthur Fellow.

UC Berkeley Launches New Molecular Therapeutics Initiative to Accelerate Drug Discovery

Retrieved on: 
木曜日, 3月 14, 2024
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, University, Education, Gene editing, Data science, Drug discovery, Patient, UCB, UC, Artificial intelligence, Chemical biology, Proximity, Cell biology, Cancer, Faculty, Protein, Student, MTI, Doctor of Philosophy, Therapy, Howard Hughes Medical Institute, MTX, University of California, Berkeley, Toxicology, DSM-IV codes, Pharmaceutical industry

The University of California, Berkeley Molecular Therapeutics (MTx) division of the Molecular & Cell Biology department today announced the launch of a new initiative to accelerate drug discovery at the interface of academia and biotech.

Key Points: 
  • The University of California, Berkeley Molecular Therapeutics (MTx) division of the Molecular & Cell Biology department today announced the launch of a new initiative to accelerate drug discovery at the interface of academia and biotech.
  • The UC Berkeley Molecular Therapeutics Initiative (MTI) will create a foundational bridge between fundamental research in rare neurological and metabolic diseases and drug discovery to identify and accelerate novel therapeutic modalities into the clinic.
  • “UC Berkeley is an international nucleus for scientific breakthroughs, such as gene editing and immuno-oncology.
  • “In this way, we are not only advancing R&D but also democratizing it by building industry connections for emerging researchers interested in pursuing a biotech career.”
    The UC Berkeley Molecular Therapeutics Initiative (MTI) seeks to accelerate drug discovery efforts by creating therapeutic modalities that overcome challenges in druggability and address unmet medical need.

"Double Life" of Key Immune Protein Reveals New Strategies for Treating Cancer and Autoimmune Diseases

Retrieved on: 
金曜日, 3月 8, 2024
Bangladesh Technical Education Board, University of Oslo, Cancer, University, The central science, Immune system, Research, Doctor of Philosophy, Science Immunology, National Institutes of Health, MD, Moses Austin, Neoplasm, Inflammation, Wang, Wellcome Trust, Rheumatology, Lupus, PD-1, Bristol Myers Squibb, Howard Hughes Medical Institute, Biochemistry, NYU, Autoimmunity, Perlmutter, Rheumatoid arthritis, Pathology, Ligand, Pharmacology, NYU Langone Health, Patient, Hanmi Pharmaceutical, Internal medicine, Biomedical sciences, Funding of science, Columbia University, Mouse, Vaccine

The same findings also support experimental treatment strategies for autoimmune diseases, in which the immune system attacks the body, because stimulating the action of PD-1, as opposed to restricting it, can potentially block an overactive immune response.

Key Points: 
  • The same findings also support experimental treatment strategies for autoimmune diseases, in which the immune system attacks the body, because stimulating the action of PD-1, as opposed to restricting it, can potentially block an overactive immune response.
  • The study results revolve around the body's immune system, which is primed to attack virally infected and cancerous cells while leaving normal cells alone.
  • The immune system recognizes tumors as abnormal, but cancer cells can hijack checkpoints to turn off immune responses.
  • At the same time, PD-1 signaling is slowed in autoimmune diseases like rheumatoid arthritis, lupus, and type 1 diabetes, such that the action of unchecked immune cells creates inflammation that can damage tissues.

Dr. David Liu Joins GenScript's Scientific Advisory Board to Guide Company's Innovation Strategy

Retrieved on: 
金曜日, 3月 8, 2024
Therapy, DNA, Multimedia, Chemistry, Library, Synthetic biology, SAB, Deletion, Harvard University, Drug discovery, PACE, Broad Institute, Howard Hughes Medical Institute, Health, Patient, Protein, Knowledge, Publication, Biology, Research, Medical device

PISCATAWAY, N.J., March 8, 2024 /PRNewswire/ -- GenScript, a global leader in life science research and application services, is excited to announce that Dr. David R. Liu, a prominent figure in the field of genome editing, has been appointed to the company's scientific advisory board (SAB).

Key Points: 
  • PISCATAWAY, N.J., March 8, 2024 /PRNewswire/ -- GenScript, a global leader in life science research and application services, is excited to announce that Dr. David R. Liu, a prominent figure in the field of genome editing, has been appointed to the company's scientific advisory board (SAB).
  • "We are thrilled to have Dr. David Liu on board to guide our initiatives," said Sherry Shao, Rotating Chief Executive Officer of GenScript.
  • "Dr. Liu's extensive knowledge and innovation will be instrumental to GenScript as we strive to enhance our platform with the aim of accelerating transformative breakthroughs to patients."
  • With Dr. Liu's addition, GenScript's SAB now encompasses leading experts across the full spectrum of genome editing and cell and gene therapy.